Business Wire

ShadowDragon Sets a New Standard in Link Analysis, Monitoring, & OSINT by Launching Multilingual Suite

10.2.2025 16:21:00 CET | Business Wire | Press release

Share

ShadowDragon Horizon - Empowering Global Investigations in Spanish, French, Italian, German—and More Languages on the Horizon

ShadowDragon, a leader in digital investigations and open-source intelligence (OSINT) solutions, today announced the launch of Horizon in multiple languages. Effective immediately, this flagship tool—previously available in English—is now fully localized in Spanish, French, Italian, and German, with additional languages slated for release in the coming months. By expanding language support, ShadowDragon becomes the first in the industry to offer a comprehensive suite of advanced OSINT capabilities designed to serve a wide range of global investigators, law enforcement, and intelligence agencies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207507777/en/

“ShadowDragon has always led the way in building robust OSINT solutions that keep pace with today’s complex global landscape,” said Daniel Clemens, CEO and Founder of ShadowDragon. “By providing our solutions in multiple languages, we reaffirm our commitment to supporting investigations, data scientists, business intelligence, and robust due diligence processes around the world—particularly in regions where language barriers have historically affected use of advanced data visualization tools. We spent a long time building this component to allow analysts to collect, analyze and investigate data and tell the story in their own language.”

Why This Matters for Global Investigations

  1. Accelerated Case Resolution
    With user interfaces, documentation, and workflows now available in Spanish, French, Italian, and German, local and cross-border investigative teams can focus on gathering actionable intelligence — leading to quicker resolutions.
  2. Enhanced Collaboration Across Borders
    International investigations often involve partners from diverse linguistic backgrounds. Harmonizing data and workflows in multiple languages removes communication hurdles, yielding more reliable intelligence and smoother cooperation.
  3. Industry-First Multilingual OSINT Leader
    As the first OSINT provider to fully localize its core offerings across these major languages, ShadowDragon sets a new standard for accessibility and operational readiness in digital investigations.

Commitment to Global Customers

This launch underscores ShadowDragon’s long-term dedication to serving a diverse, international client base that requires cutting-edge OSINT solutions. Users can rely on in-language technical support, ongoing product updates, and comprehensive educational resources to help them get the most out of these new language capabilities from day one.

About ShadowDragon

ShadowDragon provides comprehensive digital tools for modern investigations, open source intelligence collection, tailored monitoring, and investigative platform for cyber investigative resources and training for use by private companies, intelligence gathering professionals, law enforcement, and government. The U.S.-based company delivers open-source intelligence (OSINT) from over 200 networks including social media platforms, chat rooms, forums, historical datasets, and the dark web. The company monitors malware history, data breach dumps, and other areas for active cyber threats. These data collection and analytic tools help defend against malicious acts in the digital and physical world. For more information, visit www.shadowdragon.io. Visit the ShadowDragon Trust Center for details about the company’s approach to “OSINT for good.”

For more information on ShadowDragon’s multilingual product suite or upcoming language releases, visit www.shadowdragon.io.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250207507777/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye